文献速递胸部肿瘤放疗放疗物理与技术

退伍军人事务合作研究项目2005(VALOR)立体定向体部放疗的集中质量保证:可手术早期非小细胞肺癌肺癌手术或立体定向放疗的3期随机试验

Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR).
PubMed 文献 · Pract Radiat Oncol · 2024-09-02

该3期VALOR研究实施集中质量保证(QA)以降低方案偏离风险,本文总结前100例接受立体定向体部放疗(SBRT)参与者的质量与依从性。2017年4月至2022年10月回顾前100例肺部SBRT治疗计划,肿瘤轮廓均适当,98%处方适当,2例中央肿瘤使用周围肿瘤剂量处方,高剂量适形性100%可接受或偏差可接受。结论认为前100例SBRT参与者治疗适当且无安全性担忧,对错误处方的反应促成预防措施且未再复发。

要点

  • 前100例肺部SBRT计划中肿瘤轮廓均适当,98%处方适当。
  • 2%病例PTV外扩小于最小5 mm要求,2例中央肿瘤使用周围肿瘤剂量处方。
  • PTV V100%除1例外均高于方案定义最低值94%,高剂量适形性100%可接受或偏差可接受。

核心结论

  • 前100例随机接受SBRT的参与者得到适当治疗且无安全性担忧。
  • 对错误处方的反应促成预防措施,未再出现复发。
  • 该集中QA项目在无既往集中放疗QA经验的医疗系统中建立,可作为其他机构的参考。

研究设计与样本

  • 3期退伍军人事务肺癌手术或立体定向放疗研究(VALOR)实施集中质量保证(QA)以降低方案偏离风险。
  • 集中QA项目要求改编自美国国家癌症研究所影像与放射肿瘤学核心(IROC)为美国国家癌症研究所国家临床试验网络资助临床试验提供监督所建立的方案。
  • 本报告总结该研究中前100例接受SBRT参与者的质量与依从性。

主要发现

  • 2017年4月至2022年10月回顾前100例肺部SBRT治疗计划。
  • 肿瘤轮廓在所有提交中均适当;计划靶区(PTV)外扩在2%病例中小于最小5 mm要求。
  • 危及器官关键结构轮廓准确率:近端支气管树75%、气管92%、食管100%、脊髓100%、臂丛95%。
  • 处方在98%病例中适当;2例中央肿瘤使用周围肿瘤剂量处方同时满足危及器官约束。
  • PTV V100%(接受100%或以上处方剂量的靶区体积百分比)除1例外均高于方案定义最低值94%;PTV内中位最大剂量(Dmax)为125.4%(范围105.8%-149.0%;标准差±8.7%),数值为处方剂量百分比。

关键数值与推荐

  • PTV外扩最小要求为5 mm,2%病例低于该要求。
  • PTV V100%方案定义最低值为94%,除1例外均高于该值。
  • PTV内中位Dmax为125.4%(105.8%-149.0%;SD ± 8.7%),数值为处方剂量百分比。
  • 高剂量适形性在100%病例中可接受或偏差可接受。
  • 中等剂量紧凑度(R50%和D2cm)在94%病例中可接受或偏差可接受。

临床怎么用

  • 该集中QA项目在无既往集中放疗QA经验的医疗系统中建立,可作为其他机构的参考。
  • 对错误处方的反应促成预防措施且未再复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase 3 Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy study implemented centralized quality assurance (QA) to mitigate risks of protocol deviations. This report summarizes the quality and compliance of the first 100 participants treated with stereotactic body radiation therapy (SBRT) in this study. METHODS AND MATERIALS: A centralized QA program was developed to credential and monitor study sites to ensure standard-of-care lung SBRT treatments are delivered to participants. Requirements were adapted from protocols established by the National Cancer Institute's Image and Radiation Oncology Core, which provides oversight for clinical trials sponsored by the National Cancer Institute's National Clinical Trials Network. RESULTS: The first 100 lung SBRT treatment plans were reviewed from April 2017 to October 2022. Tumor contours were appropriate in all submissions. Planning target volume (PTV) expansions were less than the minimum 5 mm requirement in 2% of cases. Critical organ-at-risk structures were contoured accurately for the proximal bronchial tree, trachea, esophagus, spinal cord, and brachial plexus in 75%, 92%, 100%, 100%, and 95% of cases, respectively. Prescriptions were appropriate in 98% of cases; 2 central tumors were treated using a peripheral tumor dose prescription while meeting organ-at-risk constraints. PTV V100% (the percentage of target volume that receives 100% or more of the prescription) values were above the protocol-defined minimum of 94% in all but 1 submission. The median dose maximum (Dmax) within the PTV was 125.4% (105.8%-149.0%; SD ± 8.7%), where values reference the percentage of the prescription dose. High-dose conformality (ratio of the volume of the prescription isodose to the volume of the PTV) and intermediate-dose compactness [R50% (ratio of the volume of the half prescription isodose to the volume of the PTV) and D2cm (the maximum dose beyond a 2 cm expansion of the PTV expressed as a percentage of the prescription dose)] were acceptable or deviation acceptable in 100% and 94% of cases, respectively. CONCLUSIONS: The first 100 participants randomized to SBRT in this study were appropriately treated without safety concerns. A response to the incorrect prescriptions led to preventative measures without further recurrences. The program was developed in a health care system without prior experience with a centralized radiation therapy QA program and may serve as a reference for other institutions.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ritter TA, Timmerman RD, Hanfi HI, et al. Centralized Quality Assurance of Stereotactic Body Radiation Therapy for the Veterans Affairs Cooperative Studies Program Study Number 2005: A Phase 3 Randomized Trial of Lung Cancer Surgery or Stereotactic Radiotherapy for Operable Early-Stage Non-Small Cell Lung Cancer (VALOR). Pract Radiat Oncol. 2024. PMID: 39233006. doi:10.1016/j.prro.2024.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。